Evidence map›Paper›PMID 32431692›Full record

ArticleFrontiers in immunology2020

Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.

Mariapaola Marino, Umberto Basile, Gregorio Spagni, Cecilia Napodano, Raffaele Iorio, Francesca Gulli, Laura Todi, Carlo Provenzano, Emanuela Bartoccioni, Amelia Evoli

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 4 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 4 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Rituximab for myasthenia gravis.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Efficacy and safety of different dosages of rituximab for myasthenia gravis: a single-arm meta-analysis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis.Neurology(R) neuroimmunology & neuroinflammation · 2024
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Mariapaola MarinoIstituto di Patologia Generale, Università Cattolica del Sacro Cuore, Rome, Italy.
Umberto BasileArea Diagnostica di Laboratorio, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Gregorio SpagniIstituto di Neurologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Cecilia NapodanoIstituto di Medicina Interna, Università Cattolica del Sacro Cuore, Rome, Italy.
Raffaele IorioDipartimento di Neuroscienze, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Francesca GulliDipartimento di Medicina di Laboratorio, Ospedale Madre Giuseppina Vannini, Rome, Italy.
Laura TodiIstituto di Patologia Generale, Università Cattolica del Sacro Cuore, Rome, Italy.
Carlo ProvenzanoIstituto di Patologia Generale, Università Cattolica del Sacro Cuore, Rome, Italy.
Emanuela BartoccioniIstituto di Patologia Generale, Università Cattolica del Sacro Cuore, Rome, Italy.
Amelia EvoliIstituto di Neurologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Agostino Gemelli University Polyclinic · ITUniversità Cattolica del Sacro Cuore · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITOspedale Garibaldi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of rituximab (RTX), an anti-CD20 monoclonal antibody (Ab), in refractory myasthenia gravis (MG) is associated with a better response in patients with Abs to the muscle-specific tyrosine kinase (MuSK) than in other MG subgroups. Anti-MuSK Abs are mostly IgG4 with proven pathogenicity and positive correlation with clinical severity. The rapid and sustained response to RTX may be related to MuSK Ab production by short-lived Ab-secreting cells derived from specific CD20

Indexed as

AdolescentAdultAgedAutoantibodiesFemaleHumansImmunoglobulin GMaleMiddle AgedMyasthenia GravisReceptor Protein-Tyrosine KinasesReceptors, CholinergicRetrospective StudiesRituximabAutoantibodiesImmunoglobulin GMUSK protein, humanReceptor Protein-Tyrosine KinasesReceptors, CholinergicRituximabantibodiesIgG4MuSKmyasthenia gravisplasmablastsplasma cellsrituximabshort-lived antibody-secreting cells

Identifiers

PMID32431692
PMCPMC7214629
OpenAlexW3022437762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.